Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Interleukin1 Receptor Antagonist (human Isoform X Reduced),n2-l-methionyl- (9ci)
Molecular Weight | 509.6 g/mol |
---|---|
Molecular Formula | C20H23N5O7S2 |
XLogP3 | 1.1 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 10 |
Exact Mass | 509.10389044 g/mol |
Monoisotopic Mass | 509.10389044 g/mol |
Topological Polar Surface Area | 227 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 961 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Details:
Kineret (anakinra) is an anti-inflammatory medicine that neutralises the biological activity of both cytokines IL-1α and β, which play a role in COVID19-induced hyperinflammation.
Lead Product(s): Anakinra
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Kineret
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2022
Lead Product(s) : Anakinra
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kineret® Authorised For Emergency Use By Fda For The Treatment Of COVID-19 Related Pneumonia
Details : Kineret (anakinra) is an anti-inflammatory medicine that neutralises the biological activity of both cytokines IL-1α and β, which play a role in COVID19-induced hyperinflammation.
Product Name : Kineret
Product Type : Large molecule
Upfront Cash : Not Applicable
November 10, 2022
Details:
The study demonstrated that patients treated with anakinra were significantly more improved than those treated with placebo. Early and targeted use of anakinra, in addition to current SOC, reduces risk of death, reduces ICU admission and increases chances of full recovery.
Lead Product(s): Anakinra
Therapeutic Area: Infections and Infectious Diseases Brand Name: Kineret
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2021
Lead Product(s) : Anakinra
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The study demonstrated that patients treated with anakinra were significantly more improved than those treated with placebo. Early and targeted use of anakinra, in addition to current SOC, reduces risk of death, reduces ICU admission and increases chance...
Product Name : Kineret
Product Type : Large molecule
Upfront Cash : Not Applicable
September 03, 2021
Details:
In patients with a poor prognosis, early and targeted use of anakinra in addition to existing standard of care reduced death or progression to severe respiratory failure, while increasing the number of patients discharged with no evidence of COVID-19 infection.
Lead Product(s): Anakinra
Therapeutic Area: Infections and Infectious Diseases Brand Name: Kineret
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Hellenic Institute for the Study of Sepsis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2021
Lead Product(s) : Anakinra
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Hellenic Institute for the Study of Sepsis
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In patients with a poor prognosis, early and targeted use of anakinra in addition to existing standard of care reduced death or progression to severe respiratory failure, while increasing the number of patients discharged with no evidence of COVID-19 inf...
Product Name : Kineret
Product Type : Large molecule
Upfront Cash : Not Applicable
May 03, 2021
Details:
NICE has approved Kineret (anakinra) to treat systemic juvenile idiopathic arthritis (sJIA) in people aged eight months or over with a body weight of 10kg or more, who have not responded to at least one conventional disease modifying antirheumatic drug (DMARD).
Lead Product(s): Anakinra
Therapeutic Area: Rare Diseases and Disorders Brand Name: Kineret
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2021
Lead Product(s) : Anakinra
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NICE Issues Positive Recommendation for Use of Kineret to Treat Still’s Disease
Details : NICE has approved Kineret (anakinra) to treat systemic juvenile idiopathic arthritis (sJIA) in people aged eight months or over with a body weight of 10kg or more, who have not responded to at least one conventional disease modifying antirheumatic drug (...
Product Name : Kineret
Product Type : Large molecule
Upfront Cash : Not Applicable
March 31, 2021
Details:
Kineret® is an interleukin-1 receptor antagonist that in the US is indicated for rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more DMARDs.
Lead Product(s): Anakinra
Therapeutic Area: Genetic Disease Brand Name: Kineret
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2021
Lead Product(s) : Anakinra
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SOBI's Kineret® (anakinra) Approved in Russia for the Treatment of CAPS
Details : Kineret® is an interleukin-1 receptor antagonist that in the US is indicated for rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more DMARDs.
Product Name : Kineret
Product Type : Large molecule
Upfront Cash : Not Applicable
February 16, 2021
Details:
The trial, which began in May, involves 20 children with Sanfilippo syndrome, who will be given anakinra, which blocks the activity of interleukin-1 (IL-1), a protein in the body that causes joint damage, thereby reducing inflammation.
Lead Product(s): Anakinra
Therapeutic Area: Genetic Disease Brand Name: Kineret
Study Phase: Phase II/ Phase IIIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2020
Lead Product(s) : Anakinra
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The trial, which began in May, involves 20 children with Sanfilippo syndrome, who will be given anakinra, which blocks the activity of interleukin-1 (IL-1), a protein in the body that causes joint damage, thereby reducing inflammation.
Product Name : Kineret
Product Type : Peptide
Upfront Cash : Not Applicable
June 24, 2020
Details:
First study to report use of anakinra to treat COVID-19 infection found that high-dose anakinra was safe and was associated with a 90% survival rate and reduced respiratory symptoms associated with severe COVID-19 infection.
Lead Product(s): Anakinra
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2020
Lead Product(s) : Anakinra
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SOBI's Anakinra Found to Decrease Covid-19 Symptoms in a Small Study
Details : First study to report use of anakinra to treat COVID-19 infection found that high-dose anakinra was safe and was associated with a 90% survival rate and reduced respiratory symptoms associated with severe COVID-19 infection.
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : Not Applicable
May 08, 2020
Details:
Swedish Orphan Biovitrum AB will begin a short-term clinical study to evaluate the efficacy and safety of anakinra and emapalumab in the treatment of hyper-inflammatory syndrome in COVID-19 disease.
Lead Product(s): Anakinra
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2020
Lead Product(s) : Anakinra
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Swedish Orphan Biovitrum AB will begin a short-term clinical study to evaluate the efficacy and safety of anakinra and emapalumab in the treatment of hyper-inflammatory syndrome in COVID-19 disease.
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : Not Applicable
March 18, 2020
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
35
PharmaCompass offers a list of Anakinra API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Anakinra manufacturer or Anakinra supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Anakinra manufacturer or Anakinra supplier.
PharmaCompass also assists you with knowing the Anakinra API Price utilized in the formulation of products. Anakinra API Price is not always fixed or binding as the Anakinra Price is obtained through a variety of data sources. The Anakinra Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Anakinra manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Anakinra, including repackagers and relabelers. The FDA regulates Anakinra manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Anakinra API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Anakinra supplier is an individual or a company that provides Anakinra active pharmaceutical ingredient (API) or Anakinra finished formulations upon request. The Anakinra suppliers may include Anakinra API manufacturers, exporters, distributors and traders.
Anakinra Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Anakinra GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Anakinra GMP manufacturer or Anakinra GMP API supplier for your needs.
A Anakinra CoA (Certificate of Analysis) is a formal document that attests to Anakinra's compliance with Anakinra specifications and serves as a tool for batch-level quality control.
Anakinra CoA mostly includes findings from lab analyses of a specific batch. For each Anakinra CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Anakinra may be tested according to a variety of international standards, such as European Pharmacopoeia (Anakinra EP), Anakinra JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Anakinra USP).